🧬 PD-L1 and dMMR/MSI-H both predict response to immunotherapy.
But they aren’t telling you the same story.
🛑 One says the immune system is being held back.
🧬 The other says the tumor is full of mistakes.
Understanding that difference changes how you think about ICIs. 🧵👇
🛑 PD-L1 = A Stop Sign
The immune system has already recognized the cancer.
The problem?
The tumor expresses PD-L1 and presses the brakes on T cells through PD-1.
💉 Checkpoint inhibitors simply remove that brake.
No brake.
T cells move again.
🧬 dMMR/MSI-H = A Typo Factory
Imagine the tumor loses its spell checker.
Every cell division creates more DNA errors.
Those errors become abnormal proteins (neoantigens).
The tumor no longer looks like “self.”
💉 Checkpoint inhibitors don’t create an immune response.
They unleash one that’s already waiting.
💡 That’s why these biomarkers are fundamentally different.
🛑 PD-L1
• Phenotypic
• Dynamic
• Changes with treatment, inflammation and biopsy site
🧬 dMMR/MSI-H
• Genotypic
• Clonal
• Usually stable across primary and metastatic disease
Before prescribing immunotherapy, ask yourself:
❓Is the immune response being suppressed?
Or…
❓Is this tumor inherently immunogenic?
💉 Same drugs.
🧠 Completely different biology.
Which explanation do you use for trainees or patients? 👇
@ASCO@myESMO@AACR@SITCancer@OncoAlert@NatureReviews
#OncoTwitter #Immunotherapy #CancerResearch #MedEd
In our RCC “Challenging Case” discussion with @PBarataMD we touched on:
✅ 1L Rx options for metastatic RCC
✅ Sequencing in 2L and beyond
✅ Sequencing after Adj Rx
Full 🗣️:
⭐️ https://t.co/EsLW0b7VMp
⭐️ “Oncology Brothers” podcast
#OncTwitter#gusm#KidneyCancer
👉Here is an updated version of the Table which I initially posted post ASH2024.
👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials.
#CLL
Pembrolizumab now @FDAOncology approved in resectable LA-HNSCC based off KEYNOTE-689:
- mEFS: 51.8 vs 30.4 most (HR: 0.73)
- Benefit greater with CPS ≥10 (HR 0.66)
- 2yr EFS: 75% vs 62%
#OncTwitter#MedTwitter@OncoAlert#ASCO25#AACR25
We released a 2 part update w/ our guest @JeffAuletta from @nmdp_org & @CIBMTR on SCT 🩸 (from our initial ep 9/25/23)
🧬 part 1: what is SCT, types & risks of SCT, how to find a donor, barriers/inequities
🧬 part 2: conditioning regimens, GvHD, toxicities & career path
Aspirin can prevent colon cancer?
ALASCCA was a mic drop presentation at GI-ASCO earlier this year, but hasn't gotten the press it deserves.
Pop: 1100 Resected colorectal cancer patients with PI3k mutation
Intervention: 160mg Aspirin x 3 years
Outcome: DFS HR .61 🤯, TTR .49
PI3k mutations occur with ~ 35% prevalence. Are these outcomes worth performing genetic testing on all patients? Or maybe all resected CRC patients should get aspirin?
All I know is I now have a big bottle of aspirin in my clinic...
https://t.co/IS2kN5HAj5
💥 Tarlatamab improves survival in 2nd line SCLC. DeLLphi-304 results demonstrated statistical significant and clinically meaningful improvement in overall survival compared to standard of care chemotherapy. #LCSM @SclcSMASHERS https://t.co/hdovGP2trW
2025 prostate cancer staging from @NCCN and @AJCCancer 8th edition
Major change in 2025 NCCN vs prior years: Very high risk disease is now per STAMPEDE criteria (not Hopkins)
Breast cancer pearl of the day to my non-breast onc specialists out there: if your patient has a very medial tumor it’s important to get a breast MRI for staging because these often drain to the IM nodes and not the axillary. Knowing if IM nodes are + is important!. #OncTwitter
Our 2025 #AMLsm updates is out! @AjHematology. An up to date one stop-shop for diagnosis, risk stratificaion and managment, inlcuding new therapuetic algorithms.
Free access to the full manuscript.
https://t.co/psrOOZ9qU5 Richard Stone @DanaFarber
CEPHEUS out! 👏 @szusmani et al.
PFS ⬆️ ⬆️ with quad in ø ASCT #MMsm. Nice discussion of similarities (many) & differences (few) vs IMROZ.
📢 CD38-VRd now the norm for many: time to shift algorithms to quad-eligible vs not regardless of ASCT plans!
https://t.co/FKOk9YdZFF
❤️🩹 Cardiotoxicity of osimertinib is real. In this Korean study, osimertinib-related cardiotoxicity was 4.7%, including 3.4% requiring cardiologic intervention. Age and previous heart conditions identified. Implications for long-lasting treatment. #LCSM . https://t.co/QbZHRk6SM3
And NOW, TOP 5 PROSTATE CANCER trials of 2024!
1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%,--Benefits seen across all subgroups with a favorable safety profile.
⛹🏼♂️A new player for doublets in mHSPC!
#ESMO24 Dr. Fred Saad @Silke_Gillessen@neerajaiims@umangtalking@DrRanaMcKay@JCO_ASCO
https://t.co/pdSS2DZJcX